Latest News

Fecal Microbiota Transplant Found Noninferior to Antibiotic as Initial Treatment for C. Diff / image credit Frederik Emil Juul, MD, PhD   Courtesy of University of Oslo
Fecal Microbiota Transplant Found Noninferior to Antibiotic as Initial Treatment for C. Diff

June 17th 2025

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose / image credit: ©New Africa/AdobeStock
Real-World Study Confirms Upadacitinib’s Efficacy in Crohn Disease Treatment: Daily Dose

May 29th 2025

Fecal Microbiota Treatment via Colonoscopy Safe, Effective for Recurrent C. Diff, Study Suggests / image credit Sahil Khanna, MBBS, Mayo Clinic, Rochester
Fecal Microbiota Treatment via Colonoscopy Safe, Effective for Recurrent C. Diff, Study Suggests

May 5th 2025

Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients
Upadacitinib Found Effective in Achieving Remission in Crohn Disease, Including Biologic-Experienced Patients

April 25th 2025

Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose / image credit: ©New Africa/AdobeStock
Guselkumab (Tremfya) Gains FDA Approval for Crohn Disease: Daily Dose

April 8th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.